Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits.
about
Cisapride for Intestinal ConstipationCisapride for intestinal constipationIrritable bowel syndrome: Is it "irritable brain" or "irritable bowel"?Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanismsIntestinal secretory mechanisms in irritable bowel syndrome-diarrheaAn Endogenous Tachykinergic NK2/NK3 Receptor Cascade System Controlling the Release of Serotonin from Colonic MucosaMechanosensory Signaling in Enterochromaffin Cells and 5-HT Release: Potential Implications for Gut InflammationNew pathophysiological mechanisms in irritable bowel syndrome.Analgesic effects of JCM-16021 on neonatal maternal separation-induced visceral pain in rats.Electrochemical measurements of serotonin (5-HT) release from the guinea pig mucosa using continuous amperometry with a boron-doped diamond microelectrode.Mucosal serotonin signaling is altered in chronic constipation but not in opiate-induced constipationElevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome.Epidermal growth factor upregulates serotonin transporter and its association with visceral hypersensitivity in irritable bowel syndromeSerotonin and GI Disorders: An Update on Clinical and Experimental Studies.The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study.Review article: intestinal serotonin signalling in irritable bowel syndrome.Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics.Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome.Melatonin inhibits tachykinin NK₂ receptor-triggered 5-HT release from guinea pig isolated colonic mucosa.S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome.LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotoninLow-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome.Role of serotonin in the pathophysiology of the irritable bowel syndrome.The enteric nervous system I: organisation and classification.The enteric nervous system III: a target for pharmacological treatment.Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndromeGastrointestinal pain in functional bowel disorders: sensory neurons as novel drug targets.Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.Rotavirus and Serotonin Cross-Talk in DiarrhoeaThe rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.A role for endogenous peptide YY in tachykinin NK(2) receptor-triggered 5-HT release from guinea pig isolated colonic mucosaRecent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease.Enteropathogenic Escherichia coli infection inhibits intestinal serotonin transporter function and expression.The effect and mechanism of electroacupuncture at LI11 and ST37 on constipation in a rat model.Effect of cerium oxide nanoparticles on intestinal serotonin in zebrafish.Serotonin Activates Bacterial Quorum Sensing and Enhances the Virulence of Pseudomonas aeruginosa in the HostSerotonin in the gastrointestinal tract.Review article: the pathogenesis of diverticular disease--current perspectives on motility and neurotransmitters.Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome.Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade.
P2860
Q24234695-962C371D-B3A2-42D9-BA08-AAE5CE6A86B0Q24240684-B40DF07B-5C26-41E5-B509-5394BEE2293DQ26769908-DE52768B-A7D6-4819-8AB7-F342D65BE08FQ26830683-BBD506F7-30A2-44A0-B1F9-384F85831DE5Q26853285-7315BCB7-20F0-4169-BF74-E29D2FFA37CAQ28081884-90EC5656-C3DA-4E1E-88EA-DC52FA8DF418Q28817153-8CDABB0A-E6BF-49BC-926C-B0B17354447BQ33432064-63D6EBA5-872F-46DD-A619-3BA3CE8C7DBBQ33672837-EBDE8D5E-BA09-4903-B48B-FDC47C4CC006Q33704293-2B7A0B19-D322-4E67-8EA2-322C73D78DEFQ33859787-49EFBDA5-932F-4DB9-9561-DCCA08ABAC7DQ33993894-8BA2E70E-3736-4861-92ED-43D2D07153FEQ34303024-FAE999E8-759E-4BC9-B8F4-B75D152275F7Q34317503-A6122EB2-8538-4D3C-B9B2-DD1E270E12E9Q34446583-267638D4-FB1C-4654-9159-A54ECBBAFB37Q34566461-24B6E8B8-4FBE-409D-82EF-85BA41ACD12BQ34603139-0CD69A84-85FB-4524-AD44-A185951B9257Q34606239-6F91A8EE-A1EF-4C99-824F-F9B4D3FEB126Q34636280-44A50282-5FD8-4146-8647-07C7977383ABQ34675807-F17A9F7E-D246-40E1-A0A4-7D71279B30C3Q34790812-CBB5CE23-C192-4177-934B-9D977574B6B9Q34992347-4DF922DA-CD34-49D6-8F4D-545C7BF1B415Q35047066-8FF7743B-8AF8-467F-AE15-62AB1F9C6407Q35129960-AE8F46EE-A1F3-4B4F-AD80-C3657A8409ADQ35163567-5DF8189E-F842-40C3-BD3F-B206F4C7CD57Q35595654-15277025-9DFD-4F42-8A61-1DAB2C02C043Q35753361-5C78E285-A34D-4C1D-B21A-7602C601DF48Q35985391-9C24C3B2-3C32-4376-8D02-0CF3E54A9537Q36086012-342A19A0-80BA-47DE-8D66-5464800F36A4Q36407290-504865FC-15CF-4208-9BE0-D186807C5FA0Q36419333-25C17312-22A7-4C6D-A30D-B4DF22942670Q36874385-CCA21550-7190-4ABF-8527-62702D26401EQ37055770-A0FCA401-D638-49CA-8E4A-5E5FB61FE29DQ37085603-2B3BEAD4-EB28-4718-A2B5-21CD8831E953Q37149344-F2098555-1F3E-40B2-885A-3C0A0252F4A4Q37149918-9F29166F-3E9F-48B1-B6EA-C550FF7C547BQ37223378-8D43C041-FE7A-41F8-9DC9-2596E56BD283Q37838476-87524290-208B-490B-9CC4-140255D7B657Q38052154-ABAFF639-34B4-436B-BC15-EB37E3D8F934Q38118478-461C03BD-3C17-4056-8E3B-A36EC11F21EC
P2860
Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Patients with constipation-pre ...... ects with normal bowel habits.
@ast
Patients with constipation-pre ...... ects with normal bowel habits.
@en
type
label
Patients with constipation-pre ...... ects with normal bowel habits.
@ast
Patients with constipation-pre ...... ects with normal bowel habits.
@en
prefLabel
Patients with constipation-pre ...... ects with normal bowel habits.
@ast
Patients with constipation-pre ...... ects with normal bowel habits.
@en
P2093
P356
P1433
P1476
Patients with constipation-pre ...... ects with normal bowel habits.
@en
P2093
P304
P356
10.1159/000051888
P577
2001-01-01T00:00:00Z